ArticleWorld journal of gastrointestinal surgery2025
Effect of nalbuphine on analgesia and pain factors after gastric cancer resection.
Article in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Sodium Channel-Selective Analgesics in Postoperative, Neuralgia, and Neuropathy-Related Pain Management: A Systematic Review and Literature Review.International journal of molecular sciences · 2025Pooled it
- Article
- Effectiveness of Non-Pharmacological Interventions on Postoperative Pain in Gastric Cancer: A Systematic Review and NMA Protocol.Journal of pain research · 2026Article
- NalbuphineWorld journal of gastrointestinal pharmacology and therapeutics · 2025Article
- Insights and progress on postoperative analgesia of radical gastrectomy for gastric cancer: a comprehensive review.Frontiers in pain research (Lausanne, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is a prevalent tumor in the digestive system, with around one million new cases reported annually, ranking it as the third most common malignancy. Reducing pain is a key research focus. This study evaluates the effect of nalbuphine on the analgesic effect and the expression of pain factors in patients after radical resection.
aimTo provide a reference for postoperative analgesia methods.
methodsOne hundred eight patients with GC, admitted between January 2022 and June 2024, underwent radical gastrectomy. They received a controlled analgesia pump and a transverse abdominis muscle plane block, divided into two groups of 54 patients in each group. The control group received sufentanil, while the observation group received nalbuphine as an analgesic. Postoperative analgesic effects, pain factor expression, and adverse effects were compared.
resultsThe resting pain and activity pain scores in the observation group at 6, 12, 24 and 48 hours were significantly lower than those in the control group. Additionally, the number of presses and consumption of the observation group at 48 hours were lower than those of the control group; and the response rate of the observation group was higher than that of the control group (
conclusionThe findings suggest that nalbuphine enhances postoperative multimodal analgesia in patients with radical GC, effectively improving postoperative analgesic effect, relieving postoperative resting and active pain, and reducing postoperative pain factor expression, demonstrating its potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.